Q BioMed, Inc's (OTCQB: QBIO) Denis Corin presents to investors at the Proactive One2One Virtual Conference.
Q BioMed is a biotech acceleration and commercial stage company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.
Price: 1.05 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has been awarded a contract with UroGPO, the largest group purchasing organization for urology private practice clinics in the US, to make its bone pain treatment Strontium89 available to doctors. Corin says through the partnership,...
Industry & services
Health
Health
Retail & consumer
